{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:32:58Z","timestamp":1788474778344,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.arbres.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:44:48Z","timestamp":1740797088000},"page":"662-668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6\u201311 Years: Actual Observations and Clinical Perspectives"],"prefix":"10.1016","volume":"61","author":[{"given":"Margarita","family":"P\u00e9rez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"te Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina de","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Morales-Tirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"L\u00f3pez-Neyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Ruiz de","family":"Valbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Sanz-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.arbres.2025.02.010_bib0155","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arbres.2025.02.010_bib0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.02.010_bib0165","first-page":"554","article-title":"Efficacy and safety of elexacaftor\u2013tezacaftor\u2013ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children (Basel Switzerland)"},{"issue":"2","key":"10.1016\/j.arbres.2025.02.010_bib0170","first-page":"281","article-title":"CFTR modulators: transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"10.1016\/j.arbres.2025.02.010_bib0175","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM199204303261804","article-title":"Prediction of mortality in patients with cystic fibrosis","volume":"326","author":"Kerem","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.arbres.2025.02.010_bib0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1183\/09031936.00091607","article-title":"Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis","volume":"33","author":"Troosters","year":"2009","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.arbres.2025.02.010_bib0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000186694","article-title":"Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases","volume":"77","author":"Ferrazza","year":"2009","journal-title":"Respiration"},{"issue":"1","key":"10.1016\/j.arbres.2025.02.010_bib0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4187\/respcare.06185","article-title":"Peak oxygen uptake and mortality in cystic fibrosis: systematic review and meta-analysis","volume":"64","author":"Vendrusculo","year":"2019","journal-title":"Respir Care"},{"issue":"11","key":"10.1016\/j.arbres.2025.02.010_bib0195","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.arbres.2025.02.010_bib0200","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcf.2022.05.009","article-title":"Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor\/Ivacaftor and Tezacaftor\/Ivacaftor","volume":"21","author":"Rysgaard","year":"2022","journal-title":"J Cystic Fibr"},{"issue":"3","key":"10.1016\/j.arbres.2025.02.010_bib0205","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2020.12.006","article-title":"VO2max as an exercise tolerance endpoint in people with cystic fibrosis: lessons from a lumacaftor\/ivacaftor trial","volume":"20","author":"Wilson","year":"2021","journal-title":"J Cystic Fibr"},{"issue":"1","key":"10.1016\/j.arbres.2025.02.010_bib0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1249\/01.mss.0000240326.54147.fc","article-title":"Effects of an intrahospital exercise program intervention for children with leukemia","volume":"39","author":"San Juan","year":"2007","journal-title":"Med Sci Sports Exerc"},{"issue":"154","key":"10.1016\/j.arbres.2025.02.010_bib0215","doi-asserted-by":"crossref","first-page":"180101","DOI":"10.1183\/16000617.0101-2018","article-title":"ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases","volume":"28","author":"Radtke","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"12","key":"10.1016\/j.arbres.2025.02.010_bib0220","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1164\/rccm.200605-642ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: pulmonary function testing in preschool children","volume":"175","author":"Beydon","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.arbres.2025.02.010_bib0225","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1183\/20734735.012717","article-title":"The Global Lung Function Initiative (GLI) Network: bringing the world's respiratory reference values together","volume":"13","author":"Cooper","year":"2017","journal-title":"Breathe (Sheffield, England)"},{"key":"10.1016\/j.arbres.2025.02.010_bib0230","first-page":"4209812","article-title":"Methods of 10-meter walk test and repercussions for reliability obtained in typically developing children","volume":"2020","author":"de Baptista","year":"2020","journal-title":"Rehabil Res Pract"},{"key":"10.1016\/j.arbres.2025.02.010_bib0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.physio.2021.03.002","article-title":"Development of stratified normative data and reference equations for the timed up and down stairs test for healthy children 6\u201314 years of age","volume":"112","author":"Del Corral","year":"2021","journal-title":"Physiotherapy"},{"issue":"5","key":"10.1016\/j.arbres.2025.02.010_bib0240","doi-asserted-by":"crossref","first-page":"907","DOI":"10.26603\/001c.36432","article-title":"Normative reference values and validity for the 30-second chair-stand test in healthy young adults","volume":"17","author":"Lein","year":"2022","journal-title":"Int J Sports Phys Ther"},{"issue":"1","key":"10.1016\/j.arbres.2025.02.010_bib0245","doi-asserted-by":"crossref","first-page":"00687","DOI":"10.1183\/23120541.00687-2023","article-title":"Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis","volume":"10","author":"Ahmed","year":"2024","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.arbres.2025.02.010_bib0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.arbres.2025.02.010_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.010","article-title":"Changes in exercise capacity in people with Cystic Fibrosis after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment \u2013 a Danish prospective cohort","author":"Philipsen","year":"2024","journal-title":"J Cystic Fibr"},{"issue":"3","key":"10.1016\/j.arbres.2025.02.010_bib0260","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcf.2019.03.001","article-title":"Effects of Lumacaftor\/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis","volume":"18","author":"Savi","year":"2019","journal-title":"J Cystic Fibr"},{"key":"10.1016\/j.arbres.2025.02.010_bib0265","first-page":"28","article-title":"Exercise testing in cystic fibrosis: who and why?","volume":"27","author":"Urquhart","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.arbres.2025.02.010_bib0270","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/2193-1801-3-696","article-title":"Ventilatory response to exercise in adolescents with cystic fibrosis and mild-to-moderate airway obstruction","volume":"3","author":"Bongers","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1016\/j.arbres.2025.02.010_bib0275","doi-asserted-by":"crossref","first-page":"1176815","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arbres.2025.02.010_bib0280","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.arbres.2025.02.010_bib0285","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2021.11.011","article-title":"Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies","volume":"21","author":"Caterini","year":"2022","journal-title":"J Cystic Fibr"},{"issue":"5","key":"10.1016\/j.arbres.2025.02.010_bib0290","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s40279-024-02007-2","article-title":"Exercise-regulated mitochondrial and nuclear signalling networks in skeletal muscle","volume":"54","author":"Reisman","year":"2024","journal-title":"Sports Med (Auckland, NZ)"},{"issue":"9","key":"10.1016\/j.arbres.2025.02.010_bib0295","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older \u2013 the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.arbres.2025.02.010_bib0300","doi-asserted-by":"crossref","first-page":"e26729","DOI":"10.1016\/j.heliyon.2024.e26729","article-title":"One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis","volume":"10","author":"Anne-Sophie","year":"2024","journal-title":"Heliyon"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T22:50:42Z","timestamp":1762037442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0300289625000717"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.02.010","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Aerobic Capacity in Children With Cystic Fibrosis Aged 6\u201311 Years: Actual Observations and Clinical Perspectives","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}